In ₹ Crore except Per Share Latest Annual | JAGSNPHARM FY26 | FERMENTA no data | AMRUTANJAN FY26 | NGLFINE FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 36.54× | — | ◆ 24.63× | 34.67× | 29.65× +23% | |
| P/B | 5.67× | — | ◆ 3.85× | 5.07× | 4.46× +27% | |
| EV/EBITDA | 26.79× | — | ◆ 18.66× | 23.87× | 21.26× +26% | |
| Market Cap | ₹1,566 Cr | — | ₹1,426 Cr | ₹1,669 Cr | ₹1,548 Cr +1% | |
| Growth | ||||||
| Revenue CAGR 3Y | 6.66% | — | 9.80% | ◆ 21.68% | 15.74% -58% | |
| Revenue CAGR 5Y | 8.85% | — | ◆ 13.96% | — | 13.96% -37% | |
| Net Income CAGR 3Y | 17.26% | — | 13.29% | ◆ 32.91% | 23.10% -25% | |
| Revenue YoY (latest Q) | 8.76% | — | 9.49% | ◆ 33.57% | 21.53% -59% | |
| Net Income YoY (latest Q) | 22.18% | — | -47.47% | ◆ 99.09% | 25.81% -14% | |
| Profitability | ||||||
| EBITDA Margin | ◆ 20.22% | — | 15.06% | 14.51% | 14.79% +37% | |
| Net Income Margin | ◆ 15.00% | — | 11.52% | 9.61% | 10.56% +42% | |
| Return on Common Equity | 15.60% | — | ◆ 15.64% | 14.62% | 15.13% +3% | |
| Return on Capital Employed | 16.86% | — | ◆ 18.13% | 13.43% | 15.78% +7% | |
| Return on Assets | ◆ 13.60% | — | 11.38% | 8.82% | 10.10% +35% | |
| Credit & Quality | ||||||
| Total Debt/Equity | ◆ 0.00× | — | 0.00× | 0.33× | 0.17× -100% | |
| Interest Coverage | 47.31× | — | ◆ 355.72× | 11.89× | 183.81× -74% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹287 Cr | — | ₹503 Cr | ₹501 Cr | ₹502 Cr -43% | |
| Net Income | ₹43.1 Cr | — | ₹57.9 Cr | ₹48.1 Cr | ₹53 Cr -19% | |
| Total Assets | ₹317 Cr | — | ₹509 Cr | ₹545 Cr | ₹527 Cr -40% | |
| EPS | ₹6.4 | — | ₹20.03 | ₹77.9 | ₹48.97 -87% | |
| Book Value per Share | ₹41.24 | — | ₹128.06 | ₹532.91 | ₹330.49 -88% | |